Chemotherapeutics and radiation stimulate MHC class i expression through elevated interferon-beta signaling in breast cancer cells

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Wan, Shan ^a   Pestka, Sidney ^a,b   Jubin, Ronald G ^b   Lyu, Yi Lisa ^a   Tsai, Yu Chen ^a   Liu, Leroy F ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b PBL InterferonSource   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; CISPLATIN; ETOPOSIDE; INTERFERON RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PACLITAXEL; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; GAMMA IRRADIATION; PARACRINE SIGNALING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; APOPTOSIS; BIOSYNTHESIS; BREAST TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; METHODOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON-BETA; INTERLEUKIN-6; INTERLEUKIN-8; NF-KAPPA B; SIGNAL TRANSDUCTION; TOPOTECAN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863291227     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032542     Document Type: Article

References (51)

1. Emens LA, Jaffee EM, (2005) Leveraging the Activity of Tumor Vaccines with Cytotoxic Chemotherapy. Cancer Research 65: 8059-8064.
2. Pasquier E, Kavallaris M, Andre N, (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7: 455-465.
3. Emens LA, (2010) Chemoimmunotherapy. Cancer J 16: 9.
4. Machiels J-PH, Reilly RT, Emens LA, Ercolini AM, Lei RY, et al. (2001) Cyclophosphamide, Doxorubicin, and Paclitaxel Enhance the Antitumor Immune Response of Granulocyte/Macrophage-Colony Stimulating Factor-secreting Whole-Cell Vaccines in HER-2/neu Tolerized Mice. Cancer Research 61: 3689-3697.
5. Salem ML, Kadima AN, El-Naggar SA, Rubinstein MP, Chen Y, et al. (2007) Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother 30: 14.
6. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, et al. (2008) Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation. Clinical Cancer Research 14: 1455-1463.
7. Vignali DAA, Collison LW, Workman CJ, (2008) How regulatory T cells work. Nat Rev Immunol 8: 523-532.
8. Berd D, Mastrangelo MJ, (1987) Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 47: 3317-3321.
9. Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, et al. (2009) Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 58: 615-628.
10. Tseng CW, Hung CF, Alvarez RD, Trimble C, Huh WK, et al. (2008) Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 14: 3185-3192.
11. Garcia-Lora A, Algarra I, Garrido F, (2003) MHC class I antigens, immune surveillance, and tumor immune escape. Journal of Cellular Physiology 195: 346-355.
12. Janeway CA, Travers P, Walport M, Shlomchik MJ, eds. (2001) Immunobiology. 5th ed: Garland Science.
13. Ohtsukasa S, Okabe S, Yamashita H, Iwai T, Sugihara K, (2003) Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. Journal of Cancer Research and Clinical Oncology 129: 719-726.
14. Fonsatti E, Nicolay HJM, Sigalotti L, Calabrò L, Pezzani L, et al. (2007) Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications. Clinical Cancer Research 13: 3333-3338.
15. Teicher BA, (2008) Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 75: 1262-1271.
16. Liu LF, Desai SD, Li TK, Mao Y, Sun M, et al. (2000) Mechanism of action of camptothecin. Ann N Y Acad Sci 922: 1-10.
17. Pommier Y, (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789-802.
18. Nio Y, Hirahara N, Minari Y, Iguchi C, Yamasawa K, et al. (2003) Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface. Anticancer Res 20: 7.
19. Hsiang Y-H, Lihou MG, Liu LF, (1989) Arrest of Replication Forks by Drug-stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin. Cancer Research 49: 5077-5082.
20. Pekarek LA, Weichselbaum RR, Beckett MA, Nachman J, Schreiber H, (1993) Footprinting of Individual Tumors and Their Variants by Constitutive Cytokine Expression Patterns. Cancer Research 53: 1978-1981.
21. Levina V, Su Y, Nolen B, Liu X, Gordin Y, et al. (2008) Chemotherapeutic drugs and human tumor cells cytokine network. International Journal of Cancer 123: 2031-2040.
22. Chopra V, Dinh TV, Hannigan EV, (1996) Angiogenin, interleukins, and growth-factor levels in serum of patients with ovarian cancer: correlation with angiogenesis. Cancer J Sci Am 2: 279-285.
23. Chopra V, Dinh TV, Hannigan EV, (1997) Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J Cancer Res Clin Oncol 123: 167-172.
24. Bander NH, Yao D, Liu H, Chen Y-T, Steiner M, et al. (1997) MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and-gamma. The Prostate 33: 233-239.
25. Zanon RG, Cartarozzi LP, Victório SCS, Moraes JC, Morari J, et al. (2010) Interferon (IFN) beta treatment induces major histocompatibility complex (MHC) class I expression in the spinal cord and enhances axonal growth and motor function recovery following sciatic nerve crush in mice. Neuropathology and Applied Neurobiology 36: 515-534.
26. Andersen JB, Hassel BA, (2006) The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: Friend or foe? Cytokine & Growth Factor Reviews 17: 411-421.
27. Champoux JJ, (2001) DNA TOPOISOMERASES: Structure, Function, and Mechanism. Annual Review of Biochemistry 70: 369-413.
28. Sun Z, Andersson R, (2002) NF-kappaB activation and inhibition: a review. Shock 18: 8.
29. MacDonald NJ, Kuhl D, Maguire D, Näf D, Gallant P, et al. (1990) Different pathways mediate virus inducibility of the human IFN-[alpha]1 and IFN-[beta] genes. Cell 60: 767-779.
30. Huang TT, Wuerzberger-Davis SM, Seufzer BJ, Shumway SD, Kurama T, et al. (2000) NF-κB Activation by Camptothecin. Journal of Biological Chemistry 275: 9501-9509.
31. Morotti A, Cilloni D, Pautasso M, Messa F, Arruga F, et al. (2006) NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line. Am J Hematol 81: 8.
32. Yeh PY, Yeh K-H, Chuang S-E, Song YC, Cheng A-L, (2004) Suppression of MEK/ERK Signaling Pathway Enhances Cisplatin-induced NF-κB Activation by Protein Phosphatase 4-mediated NF-κB p65 Thr Dephosphorylation. Journal of Biological Chemistry 279: 26143-26148.
33. Das KC, White CW, (1997) Activation of NF-κB by Antineoplastic Agents. Journal of Biological Chemistry 272: 14914-14920.
34. Habraken Y, Piret B, Piette J, (2001) S phase dependence and involvement of NF-kappaB activating kinase to NF-kappaB activation by camptothecin. Biochemical Pharmacology 62: 603-616.
35. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, et al. (1997) Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272: 21096-21103.
36. Borgne A, Versteege I, Mahe M, Studeny A, Leonce S, et al. (2006) Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment. Oncogene 25: 7361-7372.
37. Stefanis L, Park DS, Friedman WJ, Greene LA, (1999) Caspase-dependent and-independent death of camptothecin-treated embryonic cortical neurons. J Neurosci 19: 6235-6247.
38. Staudt LM, (2010) Oncogenic Activation of NF-κB. Cold Spring Harbor Perspectives in Biology 2.
39. Li N, Karin M, (1998) Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc Natl Acad Sci U S A 95: 13012-13017.
40. Zhang L, Dermawan KT, Jin ML, Xiong SD, Chu YW, (2008) Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells? Med Hypotheses 71: 802-804.
41. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, et al. (2000) Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95: 2024-2030.
42. Mokyr M, Place A, Artwohl J, Valli VE, (2006) Importance of signaling via the IFN-α/β receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor. Cancer Immunology, Immunotherapy 55: 459-468.
43. Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, et al. (1998) Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. The Journal of Clinical Investigation 101: 429-441.
44. Teitz-Tennenbaum S, Li Q, Rynkiewicz S, Ito F, Davis MA, et al. (2003) Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 63: 8466-8475.
45. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, et al. (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. The Journal of Experimental Medicine 203: 1259-1271.
46. Demidem A, Morvan D, Madelmont JC, (2006) Bystander effects are induced by CENU treatment and associated with altered protein secretory activity of treated tumor cells A relay for chemotherapy? International Journal of Cancer 119: 992-1004.
47. Kerbel RS, Kamen BA, (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436.
48. Hall EJ, (2003) The Bystander Effect. Health Phys 85: 5.
49. Kargiotis O, Geka A, Rao JS, Kyritsis AP, (2010) Effects of irradiation on tumor cell survival, invasion and angiogenesis. J Neurooncol 100: 323-338.
50. Fu X, Wan S, Lyu YL, Liu LF, Qi H, (2008) Etoposide Induces ATM-Dependent Mitochondrial Biogenesis through AMPK Activation. PLoS ONE 3: e2009.
51. Livak KJ, Schmittgen TD, (2001) Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-[Delta][Delta]CT Method. Methods 25: 402-408.